This study delved into the intricate variations in glycan structures associated with different therapeutic interventions, specifically investigating the effects of Aromatase Inhibitor (AI) therapy utilizing anastrozole and SERM therapies employing tamoxifen, in Luminal A and Luminal B subtypes of BC. This evidence concerns the gene CYP19A1 and breast cancer.